Latest Cytotoxicity Stories
SOUTH SAN FRANCISCO, Calif., July 8 /PRNewswire/ -- Calithera Biosciences, a company developing novel oncology therapeutics, today announced the completion of a Series A financing totaling $40 million. Morgenthaler Ventures led the financing with U.S.
PRINCETON, N.J., June 23 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into two agreements with GlaxoSmithKline (GSK).
NEW YORK, Dec.
SEATTLE, Nov. 11 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) announced today the acceptance of two data presentations on its product candidate, TRU-016, at the 2009 American Society of Hematology (ASH) Annual Meeting Dec. 5-8, 2009 in New Orleans, Louisiana.
PRINCETON, N.J. and WALTHAM, Mass., Oct. 21 /PRNewswire/ -- BioWa, Inc. (BioWa) and NKT Therapeutics, Inc.
PRINCETON, N.J., Oct. 5 /PRNewswire/ -- BioWa, Inc. announced today that it has entered into an agreement with Otsuka Pharmaceutical Co. Ltd.
LONDON, March 19 /PRNewswire/ -- The 2009 Frost & Sullivan European Drug Discovery Product Innovation Award is presented to Xenometrix AG in recognition of its active role in the production of single and multiple endpoint cytotoxicity assays.
Owing to the novel properties of carbon nanotubes (CBNs), a series of problems associated with in vitro toxicity assessments of carbon nanotubes (CNTs) have appeared in many literatures.
The central role of receptor tyrosine kinases (RTKs) in cellular processes, especially in cancer, has made them an important target for several antibody- and small molecule-based inhibitors specific for various RTKs for the treatment of different tumour entities.
UC Davis Cancer Center researchers have discovered a genetic switch that causes cancer cells to become more sensitive to a drug administered to enhance radiation therapy effectiveness. The switch does not make the drug more toxic.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.